Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen Launches miRNA Rx Spinout

NEW YORK (GenomeWeb News) – Asuragen today announced that it has spun out its microRNA-based therapeutics intellectual property into a new company called Mirna Therapeutics.
 
Specific details about the structure and focus of Mirna were not disclosed.
 
“The discovery of miRNAs represents a paradigm-changing event in biology and medicine of a magnitude that only occurs once every decade or two," Asuragen CEO and CSO Matt Winkler said in a statement. “They likely will become a major new class of drugs.”
 
As reported by GenomeWeb Daily News sister publication RNAi News in January, the new company is initially being funded with $3 million from Asuragen.
 

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.